Moderna's 57 GF Score and the Gap It Leaves Buyers
GuruFocus put a GF Score of 57 on Moderna as the shares traded up 2.76% on the day. Here is what a middling composite ranking does and does not tell an investor.
GuruFocus assigned Moderna Inc (MRNA) a GF Score of 57 in an August 17, 2026 assessment of the vaccine maker, published while the stock traded at 65.07, up 2.76% on the day from a prior close of 63.32.
GuruFocus has put a GF Score of 57 on Moderna Inc (MRNA), a reading that lands the vaccine maker squarely in the unremarkable middle of the research firm's composite ranking system. The assessment was published on August 17, 2026, a session in which the stock was one of the day's stronger performers: 65.07 as of 16:29 GMT, up 2.76% from the prior close of 63.32, having traded between 62.91 and 65.54.
That combination — a mediocre fundamental score alongside a firm tape — is the whole story for Moderna at this stage of its life as a public company. The score is a backward-looking summary of what the financial statements say. The share price is a forward-looking bet on what the pipeline might eventually deliver. Those two things have been pulling in opposite directions for a while, and a single-number ranking cannot arbitrate between them.
What a composite score like 57 actually measures
The GF Score is not an analyst opinion, a price target, or a recommendation. It is a rules-based blend of a company's financial strength, profitability, growth, valuation and momentum, each scored from reported data and then rolled into one figure. Companies that rank highly tend to be the boring compounders: stable margins, rising revenue, low leverage, a long history of the same numbers getting slightly better.
Moderna does not look like that. A middling score for a company of its profile almost always reflects the same underlying arithmetic — that the profitability and growth components have deteriorated from an exceptional base, dragging the composite down even when the balance sheet component holds up. The GuruFocus framing is deliberately mechanical, which is its strength and its limitation. It rewards demonstrated results and is structurally unkind to a business whose case rests on assets that have not yet generated revenue.
Investors should read a 57 as a flag rather than a verdict: the reported fundamentals are not doing the work of supporting the equity story. Something else has to.
The pipeline is the part the score cannot price
For a company like Moderna, the bull case is almost entirely about optionality — programs in development, platform reuse, regulatory catalysts, partnership economics. None of that appears in a profitability ratio until it converts into product revenue. A screening model sees only the conversion, and only after it happens.
This is why quantitative scores and biotech valuations routinely disagree. A late-stage readout can change a company's intrinsic worth by a large multiple in a single morning while leaving the trailing financial statements untouched for another two quarters. The score updates last. That is not a defect in the methodology; it is a reminder about which tool answers which question.
The practical implication for anyone using screens: a low composite score on a development-stage or post-blockbuster pharmaceutical company is not the same signal it would be on an industrial or a consumer staple. On the latter, weak fundamentals usually mean a weak business. Here, they may simply mean an earlier point in a long cycle — or genuine decline. The score alone cannot distinguish the two, and that distinction is the entire investment decision.
Monday's move against a flat broad market
The day's price action gives the ranking some useful context. Moderna's 2.76% gain came while the major benchmarks were going nowhere. The S&P 500 tracker (SPY) was at $775.28, down 0.14% on the day. The Dow 30 fund (DIA) sat at $535.35, off 0.27%. Only the Nasdaq 100 (QQQ) was higher, at $732.68, up 0.22%. All quotes are as of 16:29 GMT on August 17, 2026.
In other words, whatever bid the stock had was idiosyncratic rather than a rising-tide effect. On the day, the shares added roughly 1.75 points from the prior close — an illustrative figure derived from the quoted prices — and closed in on the upper end of a session range that spanned about 2.63 points from low to high. That is a wide intraday band relative to the price, which is characteristic of the name: liquidity is fine, conviction is not, and the stock reprices quickly on headlines.
How to use the score without being misled by it
In other words, whatever bid the stock had was idiosyncratic rather than a rising-tide effect.
Three things are worth watching from here, none of which the composite ranking will tell you in advance.
- Whether the growth component stabilizes. A score of 57 improves mechanically if revenue stops falling year over year, regardless of what management says about the future. That inflection, if it comes, shows up in the ranking with a lag.
- Cash discipline versus pipeline ambition. The financial strength input is the component most within management's control. Spending decisions made now determine whether the balance sheet remains an asset in the score or becomes another drag.
- Catalyst timing against the reporting calendar. Clinical and regulatory news moves the equity immediately; it moves the score only once it becomes revenue. Anyone trading the gap between the two needs to know which calendar they are on.
There is a broader point here about the current market. Screens and composite scores have become the default first filter for retail and institutional investors alike, and they are genuinely useful for eliminating businesses that look statistically fragile. But they encode a bias toward companies whose past resembles their future. Moderna is the archetype of a company whose past emphatically does not — a firm that saw demand of a kind almost no pharmaceutical business has experienced, and now has to build an ordinary commercial franchise in its shadow.
A 57 is the honest quantitative reading of that transition while it is still incomplete. It says the numbers do not yet justify the story. Whether the story eventually justifies the numbers is a judgment no ranking system will make for you.
Key facts
- GF Score: 57 (GuruFocus composite ranking)
- MRNA price: 65.07, +2.76%, as of 16:29 GMT Aug 17, 2026
- Prior close / day range: 63.32; 62.91–65.54
- Benchmarks same time: SPY $775.28 (-0.14%), QQQ $732.68 (+0.22%), DIA $535.35 (-0.27%)
Frequently asked questions
What is a GF Score?
The GF Score is GuruFocus's rules-based composite ranking. It blends a company's financial strength, profitability, growth, valuation and momentum into a single figure calculated from reported financial data. It is not an analyst recommendation, a price target, or a forecast, and it updates only as new reported results arrive.
What does Moderna's score of 57 imply?
It places the company in the middle of the ranking range rather than among the highest-scoring names. In practice that usually means the profitability and growth components are weak relative to the company's own history, so the reported financial statements are not, on their own, supporting the equity valuation.
How did Moderna stock trade on the day of the assessment?
As of 16:29 GMT on August 17, 2026, MRNA was quoted at 65.07, up 2.76% from a prior close of 63.32. The session range ran from 62.91 to 65.54, a wide intraday band that reflects how quickly the shares reprice on news.
Did the broad market drive the gain?
No. At the same timestamp the S&P 500 tracker SPY was down 0.14% at $775.28 and the Dow fund DIA was down 0.27% at $535.35, while the Nasdaq 100 fund QQQ was up just 0.22% at $732.68. The move in Moderna was company-specific rather than a market-wide rally.
Why do quantitative scores often understate biotech companies?
Because the value of a drug developer sits largely in programs that have not yet produced revenue. Screening models measure results that already appear in the financial statements, so clinical and regulatory progress only registers after it converts into sales. The score updates last, which creates persistent disagreement with market pricing.
What would raise the score from here?
Mechanically, the growth component improves if revenue stops declining year over year, and the financial strength component depends on cash and leverage decisions management controls. Both are reported-data inputs, so any improvement shows up in the composite with a lag behind the underlying business change.
Sources
Photo: Thirdman · Pexels Licence — source
